Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10977MR)

This product GTTS-WQ10977MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10977MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4297MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ11063MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ5776MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ5988MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ14418MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10239MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ11715MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ3867MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW